view more →
Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. Acquired by PerkinElmer (NYS: PKI) in March 2011.
view more →
Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).
view more →
Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.
view more →
Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.
view more →
Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply.
view more →
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs.
view more →
Provider of a histotripsy platform designed for the treatment of cancer. Acquired by Bezos Expeditions, Wellington K5 Global 2025
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
view more →
Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.
